Abstract Library

#3090 Retrospective Experience with Pherochromocytoma (PH) and Paraganglioma (PG) in a Single Argentinian Institution

Introduction: Pherochromocytoma (PH) and paraganglioma (PG) are neuroendocrine tumors arising in cromaffin cells in the adrenal medulla or extra adrenal paraganglia respectively. Clinical presentation is diverse. All PG/PH have malignant potential. Hereditary cases comprise up to 40% of all PG/PH.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Dioca M, Calabretta M, Iglesias L, Rojas Bilbao E, Califano I,

Keywords: Pherochromocytoma and paraganglioma (PG),

#3046 Incidence of Neuroendocrine Neoplasms Reported in England 2015-2017

Introduction: Previously published UK Cancer Registry data showed incidence of Neuroendocrine Neoplasms rising between 2001 and 2015. This was higher than had been thought (Genus et al). We report more recent data with more accurate coding (ICD-O-3).

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: White B, Bouvier C, Genus T, Rous B, Srirajaskanthan R,

Keywords: Epidemiology, Neuroendocrine Neoplasia, Incidence, Prevalence, population data, histopathology,

#2974 MEK/RAF and PARP as Novel Targets in Neuroendocrine Neoplasms – First Results from a Molecular in vitro Tumor Board

Introduction: Neuroendocrine neoplasms (NEN) are a heterogeneous group comprising well differentiated neuroendocrine tumors (NET) and poorly differentiated neuroendocrine carcinomas (NEC). Although, major progress has been made in the development of targeted therapies in various cancers, establishment of a promising personalized therapy in NEN is still pending. So far, a lack of suitable preclinical models represent a major challenge concerning the validation of a mutational based targeted therapy (MBTT)

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Viol F, Sipos B, Amin T, Fahl M, Grabowski P,

Keywords: Neuroendocrine neoplasms, Personalized therapy, Preclinical in vitro models, Mutational based targeted therapy,

#2894 Single Institution Experience with Peptide Receptor Radionuclide Therapy (PRRT) in Neuroendocrine Tumors (NET)

Introduction: Neuroendocrine tumors (NETs) are a rare and heterogenous group of tumors with rising incidence. Peptide receptor radionuclide therapy (PRRT) with radiolabeled somatostatin analogue is an encouraging systemic treatment modality with minimum side effects.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Duan H

Authors: Duan H, Ninatti G, Girod B, Ferri V, Guja K,

Keywords: NET, PRRT, ORR, PFS,

#2823 Peptide Receptor Radionuclide Therapy in Rectal Neuroendocrine Tumours

Introduction: Neuroendocrine tumours (NETs) arising from the rectum are more common in the Asian population. Current treatment options include somatostatin analogues, chemotherapy, and more recently, peptide-receptor radionuclide therapy (PRRT). Peptide receptor radionuclide therapy (PRRT) has been shown to be effective in the treatment of advanced gastroenteropancreatic (GEP) tumours with minimal adverse effects. Studies have also suggested that rectal NETs show good response to PRRT, better than GEP NETs.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Tham W, Huang H, Tai W, Yan X, Ng C,

Keywords: Neuroendocrine tumours, PRRT,